地西他滨单药与CAG/HAG方案治疗骨髓增生异常综合征难治性贫血伴原始细胞增多患者的疗效与安全性
回顾性分析121例骨髓增生异常综合征难治性贫血伴原始细胞增多(MDS-RAEB)患者,59例接受地西他滨单药(20 mg·m⁻²·d⁻¹×5 d)治疗,62例接受以低剂量阿糖胞苷为基础的CAG/HAG方案治疗。两组总反应率分别为66.2%和56.4%,差异无统计学意义;CAG/HAG组1个疗程起效率更高(94.3%对69.2%),但3~4级血细胞减少及第3个疗程感染发生率更高。结论为两方案疗效相当,CAG/HAG起效更快,地西他滨单药安全性更好。
要点
- DAC组与CAG/HAG组ORR分别为66.2%和56.4%,差异无统计学意义(P=0.276)。
- CAG/HAG组1个疗程起效率94.3%高于DAC组69.2%,起效疗程数总体比较差异有统计学意义(P=0.009)。
- CAG/HAG组3~4级血细胞减少率100.0%高于DAC组64.4%(P<0.001)。
核心结论
- 地西他滨单药与CAG/HAG方案治疗MDS-RAEB的疗效相当,CAG/HAG方案起效更快,地西他滨单药治疗安全性更好。
研究设计与样本
- 回顾性分析2008年12月至2016年10月中国医学科学院血液病医院MDS诊疗中心121例MDS-RAEB患者临床资料,59例接受地西他滨20 mg·m⁻²·d⁻¹×5 d方案治疗,62例接受CAG/HAG方案治疗。
主要发现
- DAC组与CAG/HAG组ORR分别为66.2%和56.4%,差异无统计学意义(χ²=1.185,P=0.276)。
- CAG/HAG组1个疗程起效率为94.3%,高于DAC组的69.2%,两组起效疗程数总体比较差异有统计学意义(χ²=7.612,P=0.009)。
- DAC组中位OS为19.5(95%CI 10.5~28.4)个月,CAG/HAG组为20.3(95%CI 10.7~29.9)个月,差异无统计学意义(χ²=0.004,P=0.947)。
- CAG/HAG组3~4级血细胞减少发生率为100.0%,高于DAC组的64.4%(P<0.001);CAG/HAG组第3个疗程相关感染发生率为52.9%,高于DAC组的15.2%(P=0.008)。
临床怎么用
- 原文未据此给出推荐,结论为地西他滨单药与CAG/HAG治疗MDS-RAEB疗效相当,CAG/HAG起效更快,地西他滨单药安全性更好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To observe the clinical efficacy and safety of the patients of myelodysplastic syndromes-refractory anemia with excess blasts (MDS-REAB) treated with decitabine alone or based on low dose cytarabine (Ara-C) regimen CAG/HAG [aclarubrci (ACR) /homoharring-tonine (HHT) +cytarabine+granulocyte colony stimulating factor (G-CSF) ]. Methods: Totally 121 patients with MDS-REAB were retrospectively analyzed, including 59 patients treated with decitabine alone (20 mg·m(-2)·d(-1) for 5 days) , the rest 62 ones treated with low-dose Ara-C-based regimen CAG/HAG. Overall response rate (ORR) , overall survival (OS) and adverse events of the two groups were analyzed and compared retrospectively. Results: The ORR of decitabine alone or CAG/HAG were 66.2% and 56.4% respectively, with no statistically significant differences (χ(2)=1.185, P=0.276) . Initial response rate detected by the end of first cycle of CAG/HAG was higher than that of decitabine alone (94.3% vs 69.2%) , there was statistically significant difference in the overall comparison of two groups (χ(2)=7.612, P=0.009) . The median OS of decitabine alone was 19.5 (95% CI 10.5-28.4) months, the median OS of CAG/HAG was 20.3 (95% CI 10.7-29.9) months, with no statistically significant differences (χ(2)=0.004, P=0.947) . Grade 3-4 cytopenia and infection were the most prevalent adverses of two group patients. Grade 3-4 cytopenia rate of CAG/HAG was higher than that of decitabine alone (100.0% vs 64.4%, P<0.001) . The infection rate detected at third cycle of CAG/HAG was higher than that of decitabine alone (52.9% vs 15.2%, P=0.008) . Conclusion: The efficacy of treating MDS-RAEB with decitabine alone or CAG/HAG was equivalent. CAG/HAG treatment came into effect faster, but decitabine alone treatment was safer. 目的: 比较地西他滨(DAC)单药与以小剂量阿糖胞苷(Ara-C)为基础的CAG/HAG(阿克拉霉素/高三尖杉酯碱+Ara-C+G-CSF)方案治疗骨髓增生异常综合征(MDS)难治性贫血伴有原始细胞增多(RAEB)的疗效及安全性。 方法: 回顾性分析2008年12月至2016年10月中国医学科学院血液病医院MDS诊疗中心121例MDS-RAEB患者临床资料,其中59例接受DAC 20 mg·m(-2)·d(-1)×5 d方案治疗,62例接受CAG/HAG方案治疗,比较两组患者的总反应率(ORR)、总生存(OS)率及不良反应发生率。 结果: DAC组、CAG/HAG组患者的ORR分别为66.2%和56.4%,差异无统计学意义(χ(2)=1.185,P=0.276)。CAG/HAG组1个疗程起效率明显高于DAC组(94.3%对69.2%),两组患者起效疗程数总体比较差异有统计学意义(χ(2)=7.612,P=0.009)。DAC组中位OS时间为19.5(95%CI 10.5~28.4)个月,CAG/HAG组中位OS时间为20.3(95%CI 10.7~29.9)个月,两组差异无统计学意义(χ(2)=0.004,P=0.947)。两组患者的不良反应主要是3~4级血细胞减少和相关感染,CAG/HAG组血细胞减少发生率明显高于DAC组(100.0%对64.4%,P<0.001),CAG/HAG组第3个疗程相关感染发生率明显高于DAC组(52.9%对15.2%,P=0.008)。 结论: DAC单药和CAG/HAG治疗MDS-RAEB的疗效相当,CAG/HAG方案起效更快,DAC单药治疗安全性更好。.
引用
- Xu ZF, Qin TJ, Zhang HL, et al. [The efficacy and safety of the patients of myelodysplastic syndromes-refractory anemia with excess blasts treated with decitabine alone or CAG/HAG regimen]. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 28810323. doi:10.3760/cma.j.issn.0253-2727.2017.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。